Oxurion progresses in its acquisition of Axiodis

Oxurion NV, a biopharmaceutical company based in Leuven, has lifted the condition precedent relating to the right of employees to prior information for the acquisition of a 72% stake in Axiodis CRO. This important step brings Oxurion closer to the completion of this strategic transaction by its French subsidiary.

Regulatory approval for foreign investment control in France is expected shortly. Oxurion is now focusing its efforts on completing this acquisition. At the same time, the group is pursuing other strategic collaborations, particularly in the Toulouse region, to strengthen synergies with Axiodis.

These initiatives are part of Oxurion's strategy to create an integrated hub around clinical data, meeting the needs of customers in the life sciences sector.